Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

Gustave Roussy, Cancer Campus, Grand Paris2,200 enrolled

Overview

Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

2,200

Conditions

Melanoma Non Small Cell Lung Cancer Small Cell Lung Cancer

Interventions

Blood samplePROCEDURE

Optional

Tumorous biopsyPROCEDURE

Optional

Healthy material samplePROCEDURE

Optional

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Cytological or histological diagnosis of SCLC, NSCLC or melanoma 2. Patients age \>/= 18 years old 3. Indication of treatment using platinum salts for lung cancer except for patient with NSCLC treated by surgery for whom platinum salts is not indicated 4. If a biopsy is proposed, lesion lust be easily accessible 5. Signed informed consent Exclusion Criteria: 1. Patients unable to follow the protocol 2. Consent refusal

Locations (1)

Gustave Roussy Cancer Campus Grand Paris

Villejuif, Val de Marne, France

RECRUITING

Outcomes

Primary Outcomes

Mutation rate on tumorous material

Assessed at the time of inclusion using tumorous material used for diagnosis

Time frame: Assessed at the time of inclusion

Central Contacts

Benjamin Besse, MD

CONTACT

0142114317 benjamin.besse@gustaveroussy.fr

Caroline Robert, MD

CONTACT

0142114211 caroline.robert@gustaveroussy.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.